Advertisement

Vasopressin V1-Receptor Assay in Rat Small Mesenteric Arteries

  • J. A. Angus
  • M. J. Lew
  • J. Schwartz
  • M. Ross-Smith
Part of the Experimental Biology and Medicine book series (EBAM, volume 26)

Abstract

The bioassay of vasoactive peptides has often been confined to in vivo preparations because of the lack of receptors on the traditional, robust, functional assay of an isolated large artery preparation as in the rabbit or rat aorta. The standard preparation for the bioassay of arginine vasopressin (AVP) and structural analogues, especially for the development of antagonists, has been the acute rise in blood pressure to two bolus intravenous doses of arginine vasopressin (1x and 2x) in urethane anaesthetized rats pretreated with phenoxybenzamine to antagonise αl- and α2-adrenoceptors (1). After pretreating the rats with a potential antagonist, the 1x and 2x doses of arginine vasopressin are repeated. The “effective dose” of the antagonist is then defined as the dose (nanomoles per kilogram) that reduces the rise in pressure from 2x dose of agonist to the response observed for 1x in the absence of the antagonist. By taking the volume of distribution as 67ml/kg body weight (assuming one compartment kinetics) for the antagonist, one can readily calculate a “pA2” value (-logM) for this concentration. This type of analysis in vivo assumes that (i) the antagonist drug has achieved equilibrium in the receptor biophase (ii) that the antagonist has shifted the agonist dose — pressor response curve in parallel without change in maximum and that the reduction in response from 2x to 1x dose of AVP equates with a two fold shift to the right in agonist (AVP) sensitivity. Moreover, the continued rightward shift in agonist curves with increasing dose levels of antagonist is not tested.

Keywords

Arginine Vasopressin Bolus Intravenous Dose Concentration Response Curve Small Mesenteric Artery Bowman Gray School 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Manning M, and W.H. Sawyer. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 114: 617–632, 1989.PubMedGoogle Scholar
  2. 2.
    Angus J.A., A. Broughton and M.J. Mulvany. Role of alpha—adrenoceptors in constrictor responses of rat, guinea pig and rabbit small arteries to neural activation. J. Physiol. (Lond) 403: 495–510, 1988.Google Scholar
  3. 3.
    Lammek B., P. Rekowski, G. Kupryszewski, P. Melin, and U. Ragnarsson. Synthesis of arginine-vasopressins, modified in positions 1 and 2 as antagonists of the vasopressor response to the parent hormone. J. Med. Chem. 31: 603–606, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    Kruszynski M., B. Lammek, and M. Manning [1-(ßmercapto-13,131-cyclopentamethylenepropionic acid), 2 (0-methyl) tyrosine] arginine-vasopressin and [1-(3mercapto-131 ß-cyclopentamethylenepropionic acid)] arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J. Med. Chem. 23: 364–368, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Arunlakshana O., and H. O. Schild. Some quantitative uses of drug antagonists. Brit. J. Pharmacol. 14: 48–58, 1959PubMedGoogle Scholar
  6. 6.
    Waud D.R. Analysis of dose-response curves in: Methods in Pharmacology Vol. 3. Smooth muscle, ed by E.E. Daniel and W. M. Paton, P Penum Press, New York, 1975.Google Scholar
  7. 7.
    Stone M. and J. A. Angus. Developments of computer-based estimation of pA2 values and associated analysis. J. Pharm. Exp. Thera. 207: 705–718, 1978.Google Scholar
  8. 8.
    Angus J.A., J. W. Black and M. Stone. Estimation of pKB values for histamine H2-receptor antagonists using an in vitro acid secretion assay. Brit. J. Pharmacol. 68: 413–423, 1980.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • J. A. Angus
    • 1
  • M. J. Lew
    • 1
  • J. Schwartz
    • 2
  • M. Ross-Smith
    • 1
  1. 1.Department of PharmacologyUniversity of MelbourneVictoriaAustralia
  2. 2.Department of Obstetrics and Gynaecology, The Bowman Gray School of MedicineWake Forest UniversityWinston-SalemUSA

Personalised recommendations